Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges.

Purpose Of Review: To review novel antiinfective agents in development for multidrug-resistant (MDR) Gram-negative bacterial infections.

Recent Findings: Four novel agents are in various phases of development (tebipenem, durlobactam-sulbactam, cefepime-taniborbactam, and xeruborbactam). Tebpipenem is an oral carbapenem with a recently completed phase III trial for complicated urinary tract infections while durlobactam-sulbactam represents a potential alternative for drug-resistant Acinetobacter baumannii .